GF Fund Management’s SpringWorks Therapeutics SWTX Stock Holding History

GF Fund Management’s Portfolio SWTX Stock Details SWTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-1,905	Closed	-$89.5K	–	677
2025 Q2	$89.5K	Hold	1,905	–	–	﹤0.01%	375
2025 Q1	$84.1K	Buy	1,905 +343	+22%	+$15.8K	﹤0.01%	377
2024 Q4	$56.4K	Buy	+1,562	New	+$54.6K	﹤0.01%	379

Other funds holding SWTX

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

GF Fund Management's SWTX Position: Q3 2025 in Review

GF Fund Management sold out of SpringWorks Therapeutics (SWTX) in Q3 2025, closing a stake of 1,905 shares — an estimated $89.5K sold.

GF Fund Management first reported a position in SWTX in Q4 2024 and held it in 3 quarters. The position peaked at $89.5K in Q2 2025. 3 funds tracked by Wall St. Rank hold SWTX as of Q3 2025.

GF Fund Management reported no remaining SpringWorks Therapeutics position as of Q3 2025 after selling out during the quarter.
GF Fund Management sold 1,905 SpringWorks Therapeutics shares in Q3 2025, an estimated $89.5K.
GF Fund Management first reported a position in SpringWorks Therapeutics in Q4 2024 and held it in 3 quarters.
GF Fund Management's SpringWorks Therapeutics position peaked at $89.5K in Q2 2025.
3 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q3 2025.

Based on GF Fund Management's 13F filing for Q3 2025, filed 7 Nov 2025.